CA3242074A1 - 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors - Google Patents

1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors

Info

Publication number
CA3242074A1
CA3242074A1 CA3242074A CA3242074A CA3242074A1 CA 3242074 A1 CA3242074 A1 CA 3242074A1 CA 3242074 A CA3242074 A CA 3242074A CA 3242074 A CA3242074 A CA 3242074A CA 3242074 A1 CA3242074 A1 CA 3242074A1
Authority
CA
Canada
Prior art keywords
oxazepine
pyrido
bcl
pyrrolo
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242074A
Other languages
English (en)
French (fr)
Inventor
George A. Doherty
Vikram BHAT
Patrick Brady
Yujia Dai
Jianchun Gong
Andrew S. Judd
Andrew J. Souers
Yiyun YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA3242074A1 publication Critical patent/CA3242074A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3242074A 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors Pending CA3242074A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
US63/267,018 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Publications (1)

Publication Number Publication Date
CA3242074A1 true CA3242074A1 (en) 2023-07-27

Family

ID=85382827

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242074A Pending CA3242074A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors

Country Status (13)

Country Link
US (3) US11964990B2 (cg-RX-API-DMAC7.html)
EP (1) EP4466273A1 (cg-RX-API-DMAC7.html)
JP (2) JP7714811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240136972A (cg-RX-API-DMAC7.html)
CN (1) CN119053610A (cg-RX-API-DMAC7.html)
AR (1) AR128310A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023210279A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009334A2 (cg-RX-API-DMAC7.html)
IL (1) IL312709A (cg-RX-API-DMAC7.html)
MX (1) MX2024008840A (cg-RX-API-DMAC7.html)
TW (1) TW202340210A (cg-RX-API-DMAC7.html)
WO (1) WO2023141536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022010410A (es) 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Also Published As

Publication number Publication date
AU2023210279A1 (en) 2024-05-23
JP2025504382A (ja) 2025-02-12
IL312709A (en) 2024-07-01
AR128310A1 (es) 2024-04-17
CO2024009334A2 (es) 2024-07-18
TW202340210A (zh) 2023-10-16
US20230234971A1 (en) 2023-07-27
KR20240136972A (ko) 2024-09-19
US20250066388A1 (en) 2025-02-27
MX2024008840A (es) 2024-07-25
EP4466273A1 (en) 2024-11-27
JP7714811B2 (ja) 2025-07-29
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
US20260028356A1 (en) 2026-01-29
CN119053610A (zh) 2024-11-29
JP2025160251A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
EP2295402A3 (en) Antibacterial agents
PH12021500017A1 (en) Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
MX2025010928A (es) Compuestos de alquinil quinazolina
UA84878C2 (ru) Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
IL158667A0 (en) Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
DK1159279T3 (da) 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
NZ536750A (en) 7-Aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
WO2002090332A3 (en) Novel aeylheteroalkylaminε derivatives
MX2007006497A (es) Nuevos derivados de pirrolo [3,2-d] pirimidin-4-ona y su uso en terapia.
MX2024009177A (es) Compuestos y metodos de uso
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
MX2009005982A (es) Derivados de quinolina antibacterianos.
MX2024008840A (es) Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.
WO2023141432A3 (en) Apol1 inhibitors and methods of use
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
ZA202309204B (en) Lactivicin compounds, their preparation and use as antibacterial agents
SE0302756D0 (sv) Novel Compounds
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MXPA05009688A (es) Derivados de naftiridina como agentes antibacterianos.
AU2003218130A1 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
MX2024005063A (es) Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.
CA2380455A1 (en) 9a-azalides with antibacterial activity
WO2002072581A3 (en) Pyrazolopyriadine derivatives
AU2006299042A8 (en) HIV integrase inhibitors

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217